Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six‐year experience in a large institution

por Menon, Siddharth, Davies, Amy, Frentzas, Sophia, Hawkins, Cheryl‐Ann, Segelov, Eva, Day, Daphne, Markman, Ben
Publicado 2021

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

por Frentzas, Sophia, Kao, Steven, Gao, Rang, Zheng, Hao, Rizwan, Ahsan, Budha, Nageshwar, de la Hoz Pedroza, Luz, Tan, Wei, Meniawy, Tarek
Publicado 2023

A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors

por Frentzas, Sophia, Gan, Hui K., Cosman, Rasha, Coward, Jermaine, Tran, Ben, Millward, Michael, Zhou, Yiting, Wang, Wenjing, Xia, Dennis, Wang, Zhongmin Maxwell, Li, Baiyong, Xia, Michelle, Desai, Jayesh
Publicado 2023

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

por Desai, Jayesh, Fong, Peter, Moreno, Victor, Frentzas, Sophia, Meniawy, Tarek, Markman, Ben, Voskoboynik, Mark, Rahman, Tahmina, Budha, Nageshwar, Wu, John, Marlow, Jin, Yang, Silu, Calvo, Emiliano, Martin-Liberal, Juan
Publicado 2023

TRLS-06. A Phase 1–2 clinical trial of EO1001 (APL-122), a novel irreversible pan-ErbB inhibitor with promising brain penetration

por Frentzas, Sophia, Richardson, Gary, Bacha, Jeffrey, Kanekal, Sarath, Sankar, Neil, Shen, Wang, Redkar, Sanjeev, Lai, Chinglin, Yu, Peony, Nisbet, Ian, Skoff, Kathy, Wheeler, Helen, Pedersen, Harry, Zhong, Wang Zhen, Brown, Dennis
Publicado 2021

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

por Friedlander, Michael, Mileshkin, Linda, Lombard, Janine, Frentzas, Sophia, Gao, Bo, Wilson, Michelle, Meniawy, Tarek, Baron-Hay, Sally, Briscoe, Karen, McCarthy, Nicole, Fountzilas, Christos, Cervantes, Andres, Ge, Ruimin, Wu, John, Spira, Alexander
Publicado 2023

Contrasting effects of sunitinib within in vivo models of metastasis

por Welti, Jonathan C., Powles, Thomas, Foo, Shane, Gourlaouen, Morgane, Preece, Natasha, Foster, Julie, Frentzas, Sophia, Bird, Demelza, Sharpe, Kevin, van Weverwijk, Antoinette, Robertson, David, Soffe, Julie, Erler, Janine T., Pili, Roberto, Springer, Caroline J., Mather, Stephen J., Reynolds, Andrew R.
Publicado 2012

The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial

por Masoumi-Moghaddam, Samar, Lundy, Joanne, Gao, Hugh, Rathi, Vivek, Swan, Michael, Desmond, Christopher, Bhutani, Manoop S., Southey, Melissa C., Vaughan, Rhys, Varma, Poornima, Tagkalidis, Peter, Holt, Bronte A., Pilgrim, Charles H. C., Segelov, Eva, Lee, Belinda, Harris, Marion, Strickland, Andrew, Frentzas, Sophia, Zalcberg, John, Jenkins, Brendan, Croagh, Daniel
Publicado 2021

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

por Marth, Christian, Tarnawski, Rafal, Tyulyandina, Alexandra, Pignata, Sandro, Gilbert, Lucy, Kaen, Diego, Rubio, M Jesús, Frentzas, Sophia, Beiner, Mario, Magallanes-Maciel, Manuel, Farrelly, Laura, Choi, Chel Hun, Berger, Regina, Lee, Christine, Vulsteke, Christof, Hasegawa, Kosei, Braicu, Elena Ioanna, Wu, Xiaohua, McKenzie, Jodi, Lee, John J, Makker, Vicky
Publicado 2022

Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models

por Bridgeman, Victoria L, Vermeulen, Peter B, Foo, Shane, Bilecz, Agnes, Daley, Frances, Kostaras, Eleftherios, Nathan, Mark R, Wan, Elaine, Frentzas, Sophia, Schweiger, Thomas, Hegedus, Balazs, Hoetzenecker, Konrad, Renyi‐Vamos, Ferenc, Kuczynski, Elizabeth A, Vasudev, Naveen S, Larkin, James, Gore, Martin, Dvorak, Harold F, Paku, Sandor, Kerbel, Robert S, Dome, Balazs, Reynolds, Andrew R
Publicado 2016

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

por Frentzas, Sophia, Simoneau, Eve, Bridgeman, Victoria L., Vermeulen, Peter B., Foo, Shane, Kostaras, Eleftherios, Nathan, Mark, Wotherspoon, Andrew, Gao, Zu-hua, Shi, Yu, Van den Eynden, Gert, Daley, Frances, Peckitt, Clare, Tan, Xianming, Salman, Ayat, Lazaris, Anthoula, Gazinska, Patrycja, Berg, Tracy J., Eltahir, Zak, Ritsma, Laila, Van Rheenen, Jacco, Khashper, Alla, Brown, Gina, Nystrom, Hanna, Sund, Malin, Van Laere, Steven, Loyer, Evelyne, Dirix, Luc, Cunningham, David, Metrakos, Peter, Reynolds, Andrew R.
Publicado 2016

International consensus guidelines for scoring the histopathological growth patterns of liver metastasis

por van Dam, Pieter-Jan, van der Stok, Eric P, Teuwen, Laure-Anne, Van den Eynden, Gert G, Illemann, Martin, Frentzas, Sophia, Majeed, Ali W, Eefsen, Rikke L, Coebergh van den Braak, Robert R J, Lazaris, Anthoula, Fernandez, Maria Celia, Galjart, Boris, Laerum, Ole Didrik, Rayes, Roni, Grünhagen, Dirk J, Van de paer, Michelle, Sucaet, Yves, Mudhar, Hardeep Singh, Schvimer, Michael, Nyström, Hanna, Kockx, Mark, Bird, Nigel C, Vidal-Vanaclocha, Fernando, Metrakos, Peter, Simoneau, Eve, Verhoef, Cornelis, Dirix, Luc Y, Van Laere, Steven, Gao, Zu-hua, Brodt, Pnina, Reynolds, Andrew R, Vermeulen, Peter B
Publicado 2017